Additionally, ICIs have been particularly impactful in the treatment of advanced non-small cell lung cancer (NSCLC), where therapies targeting CTLA-4, PD-1, and PD-L1 have shown promise. The gene discussed is CD274; the disease is non-small cell lung carcinoma.